The scale of QDII (Qualified Domestic Institutional Investor) funds continues to grow. According to Wind data, as of January 20, the total assets of QDII funds reached 970 billion yuan, approaching 1 trillion yuan. This represents a 59% increase compared to 610 billion yuan in the same period last year, accounting for 2.6% of the total assets in the entire fund market. Analysts believe the substantial growth in QDII fund assets reflects a rising demand among investors for global asset allocation. Although their scale remains smaller than mainstream fund products like equity funds, bond funds, and index funds, it fully demonstrates the growth potential in the cross-border investment sector. In fact, the total assets of QDII funds have been on a rapid growth trajectory since last year. Data shows that at the beginning of last year, QDII fund assets were only 610 billion yuan. They surpassed 700 billion yuan in July, broke through 900 billion yuan in September, and have now reached 970 billion yuan, standing just one step away from the 1 trillion yuan milestone. Zhu Runkang, Public Fund Product Manager at Shenzhen Qianhai Paipaiwang Fund Sales Co., Ltd., stated that the significant growth in QDII fund scale stems from the further release of investors' demand for global asset allocation, with market style rotations driving capital flows into diversified assets. On the other hand, increased investor trust in fund companies and enhanced risk tolerance are also driving the internationalization of investment portfolios. Beyond the notable growth in scale, the performance of QDII funds has also shown considerable resilience. Data indicates that since the beginning of the year, 68 products have achieved net value growth exceeding 10%. Among the top performers are mostly technology-themed products, such as China Universal Hong Kong Advantage Selection A, China Great Wall Hong Kong Healthcare Selection A, Huatai-PineBridge CSI KRX China-Korea Semiconductor ETF, and Invesco Great Wall Global Semiconductor Chip Industry A, all of which have stood out among their peers. The current mainstream allocation structure of QDII funds reveals that holdings are primarily concentrated in technology sectors like semiconductors and innovative drugs. The high growth momentum in these industries reflects global market investment opportunities and provides stable support for the performance of related funds. Li Jialiang, Fund Manager in the Index Investment Department of Southern Fund, mentioned that since the fourth quarter of last year, global semiconductor sales have seen substantial growth, with sustained industry prosperity being validated. An optimistic trend is still expected to continue into 2026. "The growth in global semiconductor revenue is primarily driven by strong demand from AI applications and data center infrastructure, which is boosting demand for logic chips and memory chips. Therefore, the semiconductor industry's upward cycle may persist through 2026," said Li Jialiang. Additionally, products such as GF China Securities Hong Kong Innovative Medicine ETF, Bosera恒生Healthcare ETF, and ChinaAMC恒生Biotech ETF have also maintained net value growth of over 10% since the start of the year. Fang Wei, Fund Manager in the Equity Investment Department of Galaxy Fund, stated that last year, "AI+" made significant breakthroughs in various areas of the medical field, including the establishment of a closed-loop ecosystem for AI+ health management and improvements in policy support systems. The synergy between commercialization capabilities and market demand has continued to boost attention on the healthcare sector. Looking ahead to 2026, "AI+" in healthcare is expected to transition from pilot phases to large-scale applications, with AI technology progressively integrating into the entire chain of R&D, diagnosis, treatment, and management, further enhancing the appeal of related sectors.
Comments